Partner With Us
● FDA • EMA • WHO-PQ • EU GMP Certified

HEALING FUTURE WITH PRECISION PHARMA

SincoPharm is a next-generation biopharmaceutical group. We discover, develop and manufacture breakthrough medicines in oncology, immunology, CNS, cardiometabolic and rare diseases — from molecule to market, for 40M+ patients worldwide.

27+
Years of pharma excellence
140+
Products & formulations
38
Clinical programs
62
Countries supplied
SincoPharm pharmaceutical laboratory
98.7% Batch Success
GMP Quality 2025 audit
🧬 mRNA + Biologics
New Suzhou Gigafactory
ONCOLOGY • VACCINES • BIOLOGICS • CNS • RARE DISEASES • GMP MANUFACTURING • CLINICAL TRIALS • ONCOLOGY • VACCINES • BIOLOGICS • CNS • RARE DISEASES • GMP MANUFACTURING • CLINICAL TRIALS • 
SincoPharm scientists in cleanroom
SincoPharm Life Science Park — 120,000 m²

R&D campus, BSL-2/3 labs, fill-finish lines, QC & stability centers.

01 — About SincoPharm

A pharma company built like a tech company. Regulated like a life depends on it.

Founded as Sino-Continental Pharm, SincoPharm (sincopharm.com) grew from a regional generics maker into an innovation-driven biopharma group with 4 R&D centers, 3 GMP mega-sites and 2,400+ people including 480 PhDs. We combine AI drug discovery, continuous manufacturing and uncompromising quality to make advanced therapies affordable.

  • ✓Mission: Deliver first-in-class and best-in-class medicines to patients faster — without compromise on safety, efficacy or access.
  • ✓Full-stack pharma: Target validation → medicinal chemistry → biologics → preclinical → Phase I-III → GMP scale-up → global distribution & pharmacovigilance.
  • ✓Quality DNA: Zero critical observations in last 6 FDA/EMA audits. QbD, PAT, data integrity ALCOA++ across all sites.
  • ✓Access commitment: Tiered pricing, voluntary licensing for LMICs, 12M vaccine doses donated 2021-2025.

🔬 480+ Scientists

Medicinal chemistry, immunology, DMPK, bioinformatics and formulation teams in Shanghai, Basel and Boston.

🏭 3 GMP Sites

Oral solid dose, sterile injectables, biologics DS/DP, mRNA LNP and lyophilization capacity 2.1B units/year.

Our therapeuticsBecome a partner
1998

Founded, first cephalosporin plant.

2008

EU GMP certification, export to 20 countries.

2016

Biologics R&D center, first mAb IND.

2022

mRNA vaccine platform, WHO PQ.

2026

AI discovery engine + 38 programs in clinic.

02 — Therapeutic areas

Where we fight disease

Six franchises, one goal: transform standard of care in high-burden and underserved diseases.

OncologyOncology

Precision Oncology

KRAS G12C/D, PARP, ADCs with topo1 payload, PD-1xLAG3 bispecifics. 11 trials in solid tumors & heme malignancies.

Vaccines immunologyVaccines & Immuno

Vaccines + Autoimmune

Quadrivalent influenza, RSV mRNA, HPV-9, IL-17 & TYK2 inhibitors for psoriasis, lupus and IBD.

CNS neurologyCNS

Neurology & Psychiatry

Alzheimer anti-amyloid, Parkinson LRRK2, treatment-resistant depression, migraine CGRP oral.

CardiometabolicCardio-metabolic

Heart & Diabetes

GLP-1/GIP dual agonist, oral PCSK9, SGLT2 + finerenone combos, once-weekly insulin.

Rare diseasesRare diseases

Orphan & Gene Therapy

AAV for hemophilia A, SMA, DMD exon-skipping, enzyme replacement for lysosomal disorders.

Anti-infectivesAnti-infectives

Infection & AMR

Novel beta-lactamase inhibitors, antifungals, long-acting HIV PrEP, TB short-course regimen.

03 — Pipeline 2026

38 programs. 14 in Phase II/III. 5 NDA filings this year.

Transparent R&D: every candidate, every phase, every readout. Data cuts updated quarterly.

CandidateIndicationModalityPhaseProgress
SCP-101 ADCHER2+ breast & gastricAntibody-drug conjugatePhase III
NDA Q4 2026
SCP-207 KRASPancreatic, CRCSmall molecule G12DPhase II
ORR 44% interim
SCP-312 mRNA-RSVRSV older adultsmRNA-LNPPhase III
28k enrolled
SCP-415 GLP-1/GIPObesity, T2DPeptide weeklyPhase IIb
-18.2% weight
SCP-520 TYK2iPsoriasis, lupusOral small moleculePhase III
2 pivotal trials
SCP-630 AAV-HAHemophilia AGene therapyPhase I/II
Durable FVIII
92%

Phase transition success vs 48% industry avg

1.8B$

R&D invested 2020-2026

240+

Patents granted, 410 pending

120+

Peer-reviewed publications

04 — R&D Engine

AI + automation + human genius

SincoPharm Discovery Cloud screens 4.2B virtual compounds in 48h. Robotic labs run 15,000 assays/week. Organ-on-chip + digital twins cut animal testing by 67%.

  • 1SincoAI: generative chemistry, AlphaFold-based epitope design, toxicity prediction with 94% accuracy.
  • 2Translational hub: patient-derived organoids, biomarkers, adaptive trial design — faster proof-of-concept.
  • 3CMC excellence: continuous manufacturing, QbD, lyophilization & LNP scale-up from mg to tons.
Collaborate on R&D
Pharma R&D automation DNA research SincoPharm
05 — Quality & Manufacturing

GMP is not a certificate. It's our culture.

🏭 Continuous Manufacturing

End-to-end continuous lines for oral solids reduce variability by 73% and lead time from 45 to 6 days. Real-time PAT release.

🧪 QC Labs 24/7

HPLC-MS, NMR, NGS, endotoxin, sterility, stability chambers ICH Q1A. 1.2M tests/year, LIMS + blockchain audit trail.

🌍 Global Supply

Cold chain 2-8°C validated to -70°C mRNA. 62 countries, 99.4% OTIF, dual sourcing for all critical APIs.

GMP manufacturing facility
Sustainability green pharma
06 — Sustainability

Net-zero pharma by 2035

Green chemistry, solvent recycling 91%, solar-powered plants, water-for-injection loop recovery. We publish full ESG + carbon footprint per product.

-48% CO₂

Scope 1+2 vs 2019 baseline

100%

Renewable electricity in EU sites

91%

Solvents recovered & reused

12M

Doses donated to LMIC programs

07 — Newsroom

Latest from SincoPharm

Clinical readouts, approvals, partnerships and science explainers. Click any story to read the full article.

No news yet

Our medical editors are preparing fresh insights on pharma innovation. Check back soon.

Pharma news

How ADCs are changing oncology

Antibody-drug conjugates deliver chemo precisely to tumor cells.

Read soon
GMP news

Inside a GMP sterile plant

What it takes to produce injectables with zero defects.

Read soon
08 — FAQ

Questions? Answered by our pharmacists.

For medical information, quality complaints or business development, contact us below. For urgent adverse events, use our 24/7 pharmacovigilance line listed in contacts.

Pharmacist consultation
What does SincoPharm produce?

Prescription medicines (Rx), biologics, vaccines, OTC and hospital injectables across oncology, immunology, CNS, cardio-metabolic, anti-infectives and rare diseases.

Are SincoPharm facilities GMP certified?

Yes. All commercial sites are EU GMP and FDA cGMP compliant, with WHO prequalification for vaccines and essential medicines. Audit reports available to partners under CDA.

How can I become a distributor?

Send your company profile, licenses, cold-chain capabilities and target portfolio via the contact form. Our alliance team replies within 3 business days.

Do you offer CDMO services?

Yes — from development to commercial: formulation, analytical, sterile fill-finish, lyophilization, biologics DS/DP and packaging with full regulatory support.

Where are clinical trial results published?

On registries and in our newsroom. We commit to publish all Phase II-III results regardless of outcome within 12 months of last patient last visit.

How do I report a side effect?

Use the contact form with subject “Pharmacovigilance” or call our 24/7 safety line. Provide product, batch, and contact for follow-up. We handle all reports per GVP.

Contact SincoPharm
09 — Contact

Let's build healthier world together

HQ: SincoPharm Tower, 88 Life Science Ave, Shanghai • Basel • Boston. Licensing, distribution, CDMO, careers.

By submitting you agree to processing of your data for business correspondence. No spam, no third-party sharing.